Abstract The prognostic outcome for hepatocellular carcinoma (HCC) remains poor. Disease progression is accompanied by dedifferentiation of the carcinoma, a process that is not well understood. The aim of this study was to get more insight into the molecular characteristics of dedifferentiated carcinomas using high throughput techniques. Microarray-based global gene expression analysis was performed on five poorly differentiated HCC cell lines compared with non-neoplastic hepatic controls and a set of three cholangiolar carcinoma (CC) cell lines. The gene with the highest upregulation was HLXB9. HLXB9 is a gene of the homeobox genfamily important for the development of the pancreas. RT-PCR confirmed the upregulation of HLXB9 in surgical specimens of carcinoma tissue, suggesting its biological significance.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignant tumor, with more than one million patients affected worldwide each year and a generally very poor prognosis [1, 2] . Large-scale gene expression profiling has provided important insights into the biology of HCC in recent years, and there have been advances in terms of HCC etiology, survival prediction, and the identification of signaling pathways that could serve as therapeutic targets [3] [4] [5] [6] [7] . Mutations in several genes (e.g., P53, IGF2R, P16, PTEN) have been associated with the development of HCC [8] .
Morphological diagnosis of HCC is guided by criteria defined in early studies still accepted as the standard for pathologists [9, 10] . Over time, HCC tends to dedifferentiate morphologically. In more than half of all patients, dedifferentiation occurs within 7-34 months of diagnosis [11, 12] . Dedifferentiation is accompanied by increasing chromosomal instability [13] . Dedifferentiation is also accompanied by the occurrence of chromosomal imbalances, such as loss of 13q, associated with loss of genes involved in cell cycle regulation and proliferation [14] . Even more dedifferentiated HCC are often difficult to separate from its cholangiocellular counterpart, i.e., cholangiocarcinoma (CC).
Because morphological dedifferentiation of HCC is associated with decreased survival time [15, 16] , it is important to elucidate the processes that lead to dedifferentiation. Towards this end, we analyzed poorly differentiated cell lines derived from HCC and CC, respectively, to search for candidate genes involved in dedifferentiation. Surgical specimens were included to determine whether these in vitro findings had biological relevance. Microarraybased global mRNA expression analysis was performed at first. Additional gene expression analysis, transfection-and RNA-silencing assays were done to verify the results.
Using this approach, we identified the homeobox gene HLXB9 as a gene that is likely to be involved in morphological dedifferentiation in a subset of HCC.
Methods

Cell lines
The HCC cell lines HLE, HLF, Huh7, HepG2, and Hep3b were kindly provided by Stefan Kubicka (Department of Gastroenterology, Hannover Medical School, Germany). The control cell lines were HHep (Provitro, Berlin, Germany), and an immortalized hepatocytic cell line (HImo, kindly provided by Prof. Dr. Didier Trono, Ecole Polytechnique Federale de Lausanne, Switzerland). Since cryopreservation can influence gene expression status [17] , experiments were performed both in freshly harvested cells and in cells that had been cryopreserved. Additionally, three CC cell lines were analyzed (EGI-1, MzCha1, TFK-1) kindly provided by Nisar Malek (Department of Gastroenterology, Hannover Medical School, Germany).
The hepatocellular origin of all HCC cell lines was confirmed by immunohistochemistry (IHC) using antibodies specific for CK8 and CK18, which are typically expressed in hepatocytic cells. CK7 and CK19 were used to exclude cholangiocellular differentiation. Ki67 was used for determination of proliferative activity (all antibodies supplied by DAKO, Hamburg, Germany). IHC was performed on histological sections of cells after formalin fixation and paraffin embedding using the cell block technique (BBCBiochemicals, Seattle, WA, USA). All HCC cell lines with the exception of Hep3b were positive for CK8 and CK18 and negative for CK7 and CK19. Hep3b showed a positive staining for CK19. The proliferation marker Ki67 was positive in 54-88% of the nuclei of cells in all HCC cell lines. Overall, proliferative activity and pleomorphism of nuclei indicated a low differentiation (data not shown).
This was comparable for the CC cell lines. Here, antibodies for CK7 and CK 19 were giving a positive staining indicating cholangiocellular differentiation. Of the nuclei, 45-55% were positive for Ki67 also indicating a high proliferative activity.
Cell culture
Cell line HImo was maintained in DMEM plus 10% fetal calf serum supplemented with glutamine and penicillin/ streptomycin at 37°C in a 5% CO 2 atmosphere using 25 cm 2 tissue culture flasks (TPP 90025, Oxoid, Prattelen, Switzerland). Cell line HHep was cultured in hepatocyte maintenance medium (Provitro, Berlin, Germany). Control cell lines were maintained as recommended by the supplier.
Tumor cell lines were incubated in DMEM with 10% fetal calf serum supplemented with glutamine and penicillin/ streptomycin at 37°C in a 5% CO 2 atmosphere.
Mycoplasma infections were excluded using the Lookout Mycoplasma PCR Detection Kit (Sigma, Germany). Growth dynamics were determined by counting cells over a period of at least 7 days. Cells were harvested in the ascending part of the growth curve.
Surgical specimens
Twenty eight tumor tissues were obtained from 27 patients as surgical specimens taken for diagnostic purposes (permitted by the Ethics Committee of the University of Bern). Tissues were paraffin-embedded after 24-h fixation in 4% formaldehyde. Histological grading of tumors was performed according to the WHO criteria [18] .
For comparison of results obtained in these specimens, we included also 10 samples of CC and five samples of hepatocellular adenoma (HCA). As a control five nonneoplastic tissues samples were chosen of livers ruptured due to trauma.
mRNA isolation
For mRNA expression analyses of the cell lines, total RNA was isolated using a commercially available system (Ambion, Cambridge, UK). Transcription to cDNA was performed using the High Capacity cDNA Reverse Transcription Kit (#4374966, Applied Biosystems, Rotkreuz, Switzerland).
Five 10-μm sections were used for total RNA isolation from formalin-fixed paraffin-embedded (FFPE) tissues. RNA was isolated exactly as described previously [19] . One section was cut for H&E staining before sectioning material for mRNA isolation, and one was cut just after sectioning. This ensured the closest proximity and greatest homogeneity of tissues used for experiments. The quality and quantity of total RNA was determined photometrically (NanoDrop Technologies, Wilmington, Germany).
Microarray analysis
A whole human genome oligonucleotide microarray kit was used for global mRNA expression analysis (array G4112F, Agilent, Waldbronn, Germany). This kit allows detection of more than 41,000 unique human transcripts. After onecolor mRNA labeling and hybridization according to the supplier's instructions, microarray images were acquired (Agilent Scanner System 2605, Waldbronn, Germany). Hybridization spots were normalized using the feature extraction software (version 9.5.3.1.) and processed as described below.
mRNA microarray data from all four cell lines and the control cell lines were further normalized and processed using GeneSpring GX software version 9.0 (Agilent, Waldbronn, Germany). GeneSpring software computes a The 15 genes with the highest fold changes for up-or downregulation, respectively, are listed here unique value for each miRNA and mRNA by taking the average of replicates spotted on the microarrays. Specimens were normalized using median normalization. HCC cell lines were taken together as one group and non-neoplastic hepatocytic cell lines as a second group. The mRNAs with a positive or negative fold change >1.5 between these two groups were further analyzed for significantly different expression using an unpaired t test and the BenjaminiHochberg calculation for multiple test controls to reduce false positive results. The level of significance was set at p<0.01.
qRT-PCR
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using mRNA obtained from cell lines was performed using the TaqMan® Universal PCR Master Mix AmpErase® (#4324018, Applied Biosystems, Rotkreuz, Switzerland) and the primers listed in Table 1 . The cycling conditions were set as instructed by the supplier. A realtime PCR system (7500, Applied Biosystems, Rotkreuz, Switzerland) was used for quantification. mRNA from FFPE samples was measured using a SuperScript™ III Platinum® One-Step qRT-PCR Kit following the instructions of the supplier (#11732020, Invitrogen, Basel, Switzerland). A 7500 Fast System (Applied Biosystems, Rotkreuz, Switzerland) was used for quantification.
siRNA-based knock down of gene expression HLXB9 was selectively suppressed by siRNA experiments using a commercially available system (On-TARGETplus SMARTpool system, Dharmacon, Chicago, IL, USA) with a specific siRNA (Human HLXB9, DHARMACON). As a negative control from the same supplier, we used the "OnTARGETplus siCONTROL Non-targeting POOL" reagents. mRNA of the manipulated cells was isolated as described above.
Transfection experiments
Immortalized hepatocytic cell line was transfected with the pCMV5-HLXB9 expression vector using the TurboFectin 8.0 reagent (Origene, Rockville, MD, USA). The media and transfection components were used exactly as specified by the supplier. The pCMV5 vector without the HLXB9 was transfected as a negative control.
Separation of subcellular compartment proteins
The Qproteome cell compartment kit (Qiagen, Hilden, Germany) was used to separate proteins in the following cellular compartments: cytosol, membranes, and nucleus. About 1×10 7 cells were harvested and lysed in accordance with the Qiagen protocol. All buffers were supplemented 
Results
Microarray-based mRNA analysis
Global mRNA expression analysis results were compared at first in HCC tumor cell lines and non-neoplastic hepatocytic cell lines (all raw data can be obtained as additional files from the authors). After use of the unpaired t test corrected for multiple testing (Benjamini-Hochberg) for all genes with a fold change >2, we identified 54 genes that were significantly up-and 125 genes that were significantly downregulated (p<0.01) in tumor cell lines ( Table 2 ). The highest fold changes were seen for MNX1 (also known as HLXB9) mRNA, which was upregulated 364-fold, and for PXDN mRNA, which was downregulated 2,199-fold (Fig. 1) . qRT-PCR was used to confirm these results (Fig. 2) . We then looked for differential expression of HCC cell lines compared to CC cell lines. Using the same criteria as described above, 986 genes were up-and 191 genes were downregulated, respectively (Table 3) .
Comparing CC cell lines with non-neoplastic cell lines led to the detection of 623 upregulated genes and 388 downregulated genes (Table 4) . Again MNX1 (HLXB9) was found upregulated with a high fold change of 572. In contrast PXDN was not dysregulated significantly.
HLXB9 expression in cell lines
Since HLXB9 is a known homeobox gene involved in the development of the pancreas and, most likely, cholangiocytes [20] , and was found upregulated in both HCC cell lines and CC cell lines, further analysis was focused onto this gene. For confirmation of the microarray based results, we selectively knocked down expression of HLXB9 in HCC cell lines by RNA interference using a known specific RNA primer. This led to the most significant decrease of HLXB9 when using a concentration of 200 mM for 24 h of incubation. HLXB9 was downregulated then to 12-29% in HCC cell lines and to 18-43% in CC cell lines, respectively (Fig. 3) . We next transfected the immortalized hepatocytic cell line with a pCMV5-HLXB9 vector. Microarray-based mRNA analysis detected a 2,383-fold increase in HLXB9 (Fig. 4) . Applying the pCMV5 vector only was giving negative results. We assumed HLXB9 as identified correctly by these experiments. Consistent with the results on mRNA expression level, HCC and CC cell lines were also positive on the protein level for HB9; HB9 was detected in the cytoplasmic and cell membrane fractions, but not in the nuclear fraction (Fig. 5) . This was confirmed by immunohistochemical analysis of HB9. HB9 staining was observed in the cytoplasm but not in the nuclei (Fig. 6 ).
HLXB9 and HB9 in surgical HCC specimens
Based on our findings, we surmised that HLXB9 was stably upregulated in HCC and CC cell lines. We next examined HLXB9/HB9 expression in surgical HCC specimens that had not been cultured by analyzing 29 surgical HCC specimens from 28 patients as well as non-neoplastic liver tissue from the same patients.
None of the 17 moderately or well-differentiated HCC tissues expressed HLXB9 mRNA, nor did the corresponding non-neoplastic tissues (Table 5 ). In contrast, 5/12 samples with low histological differentiation (Edmondson grade III or IV) [10] demonstrated HLXB9 mRNA upregulation. The ΔΔct values were generally ∼22. An exception was case B07-2284. Two samples were analyzed: one showed no upregulation of HLXB9 mRNA; the other specimen showed an upregulation compared to the non-neoplastic tissue. Interestingly, the B07-2284 tumor without upregulation had a solid growth pattern, whereas the tumor with upregulation had a pseudoglandular pattern (Fig. 7) .
We reevaluated all other poorly differentiated HCC and found that poorly differentiated HCC that lacked HLXB9 upregulation grew in a solid pattern. Two of these HCC (B04-10840 and B05-24972) demonstrated remarkable pleomorphic nuclei. In turn, poorly differentiated HCC with upregulated HLXB9 mRNA demonstrated a pseudo glandular pattern of growth. Indeed, two of these HCC were difficult to differentiate from CC (B07-23968 and B08-4419). Therefore, IHC for CK7 and CK19, respectively, was done for these cases to exclude CC and probably find progenitor cell derived subtype as described by Lee et al. [21] . These stainings were giving variable results with B08-4419 negative for CK7 and positive for CK19 and B07-23968 positive for both markers as given in Table 6 and demonstrated in Fig. 8 . Variable findings occurred also for the other three HCC analyzed as listed in that Table. In a very recently published paper of Wildenhain et al. analyzing HLXB9-TEL positive acute myeloid leukemia in children EDIL, ITGAV, KDR, SIGLEC6, CNTNAP%, ANGPT1, DSG, and ITGA9, respectively, were detected as upregulated. Since these genes are active in cell-cell contact, we reevaluated our data for these genes. Indeed we found EDIL, ITGAV, KDR, CNTNAP5, ANGPT1, ITGA as upregulated in HCC and/or CCC, too. Detailed data are given in Table 7. HLXB9 in surgical CC, HCA, and non-neoplastic specimens Upregulation of mRNA encoding HLXB9 was found in 1/10 CC sample as listed in Table 8 . In this sample, a clearly glandular pattern of growth with moderately to low differentiated tumor cells were seen. Two other CC with glandular pattern were well or moderately differentiated. Six CC revealed a solid growth pattern. No upregulation of HLXB9 was found in HCA and non-neoplastic liver samples.
Discussion
The morphological characteristics of HCC have been wellestablished since Edmondson and Steiner published their basic grading system in 1954 [9] . Most HCC demonstrate moderate differentiation at the time of surgical intervention. Well-differentiated HCC are rare, making up fewer than 10% of all HCC cases. In contrast, dedifferentiated HCC are seen more frequently as the disease progresses [11, 12] . Since dedifferentiation is accompanied by decreased survival time [15, 16] , we wished to gain insights into the mechanisms underlying dedifferentiation.
Molecular analysis of HCC biopsies is hampered by the accompanying non-neoplastic cells and by the variable morphological differentiation of the carcinomas. To avoid these issues, we began our investigation with HCC cell lines. All of these HCC cell lines were highly proliferative, which we assumed as an indicator of dedifferentiation beside the pleomorphism of these cells.
Microarray-based mRNA expression analysis of these cell lines identified a set of 54 upregulated and 125 downregulated genes in HCC. The HLXB9 gene was the most upregulated and had the highest fold increase of any gene. HLXB9 is an evolutionarily highly conserved homeobox gene that belongs to the MNX gene class [22] . It is involved in differentiation of beta cells [20] and motor neurons [23, 24] . During mouse embryonic development, HLXB9 is expressed at somite day 8 in the notochord, the dorsal gut endoderm, and the ventral endoderm at the prospective pancreatic anlage [25] . Despite PDX1 mutations that prevent pancreas development, the initial stadium of the pancreas anlage is still developing when HLXB9 is functionally expressed. HLXB9 is detected in a dorsalventral gradient during embrogenesis of mice [26] . This is in concordance with the observation that mice lacking HLXB9 are missing dorsal pancreas rudiments. HLXB9 Table 5 Expression of HLXB9 in HCC surgical specimens mutations are rare and cause Currarino syndrome, an autosomal dominant congenital malformation that causes anorectal malformations and sacral agenesis [27] .
In malignant transformed cells such as Hodgkin lymphoma cell lines, HLXB9 activates IL6 and is regulated by PI3K signaling that involves E2F3 [28] . van Bergh et al. reported a high incidence of t(7;12)(q36;p13) in infant AML with a poor outcome and ectopic expression of HLXB9. HLXB9 upregulation is mirrored by an intracellular shift away from the periphery (cytoplasm) to a more central position in the nucleus [29] . It is of high interest, that activation of IL6 together with NF-κB and dysregulation of miRNAs Lin28, and Let-7 can lead to an epigenetic shift involved in the development of a neoplastic growth of tumor cells [30] . Although we did not find direct evidence of upregulation of IL6 in the cell lines analyzed here, we assume this as an important point to consider for further research purposes.
We confirmed upregulation of HLXB9 in surgical HCC specimens in a subgroup of poorly differentiated HCC with a pseudoglandular pattern of growth. Indeed, in two samples, it was not easy to differentiate HCC from CC. We therefore looked also for expression of CK7 and CK19, since these intermediar filaments are expressed in CC and also in a subset of HCC with impaired clinical outcome [21] . Interestingly, those samples revealing upregulation of HLXB9 in our study expressed at least one of these cytokeratins in a uniform or patchy pattern. As demonstrated in the study mentioned above, this subset of HCC reveals gene expression patterns of hepatoblasts. Differentiation of hepatocytes and cholangiocytes is not finished at this time which is in concordance with the assumption that tumors cells of this particular group of HCC derive from a progenitor cell. Unfortunately in the article mentioned above, photographs of immunostainings are not given for direct comparison. Nevertheless, we assume this as an important aspect worth spending further efforts on. In contrast, to HCC with pseudo glandular pattern, HCC revealing solid growth were not associated with increased expression of HLXB9, nor were moderate-or well-differentiated HCC. By these findings, we speculate that poorly differentiated HCC with a pseudoglandular These genes are acting in cell-cell contact. Six of these genes were also found upregulated in HCC and/or CCC cell lines in our study with the fold changes given below. EDIL3 war remarkable highly expressed in CCC as discussed in the text pattern could reflect an mRNA expression pattern that is related to a cholangiolar expression pattern. This would be in concordance with the finding of upregulation of HLXB9 in the CC cell lines examined here since growth of both carcinoma types in one tumor has been reported repeatedly, HLXB9 could be a link [10] . Further, hepatocytes and cholangiocytes are assumed to be derived from hepatoblast/ oval cells, since the same progenitor cells localize to the ductal plate area [31] . Interestingly, all HCC cell lines, but only half of the surgical specimens of poorly differentiated HCC demonstrated HLXB9 upregulation. This raises the question of whether there is a bias in terms of the morphological subtype of the HCC cell line. This may be related to the observation that HCC tumor cells are difficult to establish in vitro. It seems likely that a particular subtype of HCC cell is needed for successful growth in vitro. Since the cell lines analyzed here were grown as suspensions, we cannot address this question at this time.
Very recently Wildenhain et al. [32] reported the expression of cell-cell interacting genes upregulated in childhood acute myeloid leukemia bearing a HLXB9-TEL translocation and HB9 overexpression. They found an upregulation of eight genes, six of them upregulated at least twofold in HCC and/or CCC cell lines in our study, too. EGF-like repeats and discoidin I-like domains 3 (EDIL3) was found upregulated highest in both tumor types. This gene encodes the protein of an integrin ligand. It is important in mediating angiogenesis and probably plays a role in vessel wall remodeling and development (as describe in RefSeq). Interestingly, EDIL3 is correlated to a shorter survival of HCC patients as reported by Sun et al. [33] . As HCC and CCC of low differentiation are correlated to a shorter survival of patients and also express HLXB9 in a number of such tumors as shown here, it may be speculated that there could be a link. Unfortunately, Sun et al. did not provide their data in regard to the grading of the tumors analyzed.
In conclusion, HLXB9 is significantly upregulated in HCC and CCC cell lines and in poorly differentiated HCC with a pseudoglandular pattern. The protein encoded by HLXB9, HB9, is found only in the membrane and cytoplasm of these tumor cells. This observation may provide insights into the mechanism(s) underlying development of malignancy and dedifferentiation in hepatocellular and cholangiolar cells.
